Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Cancer J. 2011 Nov;17(6):465–476. doi: 10.1097/PPO.0b013e31823dec8d

Table 4.

Studies with Dasatinib as Salvage Therapy for Imatinib Resistance or Intolerance

Study Disease
Stage		 Dose N % Response
CHR Cytogenetic Response
MCyR CCyR
Phase I52 CP 15–240 mg
daily		 40 92 45 35
AP 11 45 27 18
MBP 23 35 35 26
LBP/Ph+ ALL 10 70 80 30
START-C53 CP 70 mg twice daily 387 90 59 49
START-A54 AP 70 mg twice daily 174 45 39 32
START-B55 MBP 70 mg twice daily 109 27 33 27
START-L55 LBP 70 mg twice daily 48 29 52 46
START-R57 CP 70 mg twice daily 101 93 53 44
Dose Optimization58 CP 100 mg daily 167 92 63 50

Abbreviations: AP, advanced phase; BP, blast phase (myeloid [M] or lymphoid [L]); CCyR, Complete Cytogenetic Response; CHR, Complete Hematological Response; CP, Chronic Phase; MCyR, Major Cytogenetic Response Ph+-ALL, Philadelphia-Positive Acute Lymphoblastic Leukemia;